What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
Stada said on Friday the private equity-backed company would buy six consumer healthcare products from British GlaxoSmithKline to bolster the generic drugmaker’s presence in Europe.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
The spread of superbugs resistant to antimicrobial drugs shows no sign of slowing in Europe, health officials said, making food poisoning and other infections more difficult to treat.
More than 130,000 people were newly diagnosed with HIV last year in Eastern Europe – the highest rate ever for the region – while the number of new cases in Western Europe declined, global public health experts said.
President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.
Cancer will claim the lives of 9.6 million people in 2018, accounting for one in eight of all deaths among men and one in 11 among women, the WHO’s cancer research agency said.
The number of people dying from heatwaves is likely to rise sharply in some regions by 2080 if policymakers fail to take mitigating steps in climate and health policies, according to the results of a study.
CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.
Amgen Inc. said the U.S. FDA approved its drug Xgeva to prevent fractures in patients with multiple myeloma.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!
